Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| 1 |
Gilead Sciences
GILD
|
$2.26B |
| 2 |
Carrier Global
CARR
|
$1.12B |
| 3 |
Chevron
CVX
|
$922M |
| 4 |
Comcast
CMCSA
|
$920M |
| 5 |
Philip Morris
PM
|
$876M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.5B |
| 2 |
Netflix
NFLX
|
$1.73B |
| 3 |
Meta Platforms (Facebook)
META
|
$1.61B |
| 4 |
TransDigm Group
TDG
|
$850M |
| 5 |
Abbott
ABT
|
$773M |
Sector Composition
| 1 | Healthcare | 20.46% |
| 2 | Technology | 19.55% |
| 3 | Communication Services | 14.69% |
| 4 | Consumer Discretionary | 11.55% |
| 5 | Industrials | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Sea Limited
SE
$110B
| $532M | 0.17% | 4,960,782 +1,539,257 | +45% | +$165M |
|
127
Ultragenyx Pharmaceutical
RARE
$2.89B
| $530M | 0.17% | 6,779,565 +205,605 | +3% | +$16.1M |
|
128
Duke Energy
DUK
$95.3B
| $530M | 0.17% | 6,630,243 -189,452 | -3% | -$15.1M |
|
129
Caterpillar
CAT
$196B
| $519M | 0.16% | 4,101,767 +2,156,253 | +111% | +$273M |
|
130
SS&C Technologies
SSNC
$21.7B
| $515M | 0.16% | 9,123,575 +3,992,206 | +78% | +$225M |
|
131
Lockheed Martin
LMT
$106B
| $515M | 0.16% | 1,411,240 -2,066,548 | -59% | -$754M |
|
132
Allogene Therapeutics
ALLO
$251M
| $514M | 0.16% | 12,008,769 +3,036,198 | +34% | +$130M |
|
133
Woodward
WWD
$14.8B
| $500M | 0.16% | 6,447,414 -283,518 | -4% | -$22M |
|
134
Cenovus Energy
CVE
$29.9B
| $498M | 0.16% | 106,420,580 +42,161,825 | +66% | +$197M |
|
135
Nice
NICE
$8.73B
| $496M | 0.16% | 2,619,581 +212,024 | +9% | +$40.1M |
|
|
BLUE
136
DELISTED
bluebird bio
BLUE
| $494M | 0.16% | 8,094,771 +1,282,359 | +19% | +$78.3M |
|
137
Telus
TU
$25.1B
| $470M | 0.15% | 28,022,167 +8,942,686 | +47% | +$150M |
|
138
Peloton Interactive
PTON
$3.1B
| $466M | 0.15% | 8,061,158 +531 | +0% | +$30.7K |
|
|
GWPH
139
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $455M | 0.14% | 3,707,662 +559 | +0% | +$68.6K |
|
140
Waste Management
WM
$91.2B
| $446M | 0.14% | 4,214,930 -188,241 | -4% | -$19.9M |
|
141
Alexandria Real Estate Equities
ARE
$14.1B
| $439M | 0.14% | 2,707,873 +208,243 | +8% | +$33.8M |
|
142
Integra LifeSciences
IART
$1.18B
| $438M | 0.14% | 9,330,446 +176,447 | +2% | +$8.29M |
|
143
Otis Worldwide
OTIS
$33.9B
| $438M | 0.14% | +7,700,502 | New | +$438M |
|
144
Merck
MRK
$210B
| $432M | 0.14% | 5,588,853 +6,750 | +0.1% | +$522K |
|
145
Petrobras
PBR
$79.9B
| $428M | 0.14% | 51,794,795 +31,574,460 | +156% | +$261M |
|
|
ALLK
146
DELISTED
Allakos
ALLK
| $412M | 0.13% | 5,734,398 +211,940 | +4% | +$15.2M |
|
147
MongoDB
MDB
$25.7B
| $406M | 0.13% | 1,792,466 -323,010 | -15% | -$73.1M |
|
|
AYX
148
DELISTED
Alteryx, Inc.
AYX
| $399M | 0.13% | 2,427,215 +1,559,714 | +180% | +$256M |
|
149
Booking.com
BKNG
$181B
| $390M | 0.12% | 245,197 -140,819 | -36% | -$224M |
|
150
Royal Bank of Canada
RY
$205B
| $373M | 0.12% | 5,493,243 -4,676,779 | -46% | -$317M |
|